In this article:

Mizuho Securities Sticks to Their Buy Rating for Avrobio (AVRO)

In this article:
In this article:

Mizuho Securities analyst Uy Ear maintained a Buy rating on Avrobio (AVROResearch Report) today and set a price target of $6.00. The company’s shares closed last Wednesday at $2.29.

Avrobio has an analyst consensus of Moderate Buy, with a price target consensus of $5.40, which is an 115.1% upside from current levels. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $14.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $20.07 and a one-year low of $3.17. Currently, Avrobio has an average volume of 422.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on gene therapy for fabry, gaucher, pompe disease, and cystinosis. These gene therapies, on which the company was founded, were developed by Dr. Jeffrey Medin and Dr. Christopher Paige at the University Health Network. AvroBio launched in 2015, is headed by Co-Founder, President and CEO Geoff Mackay, and is headquartered in Cambridge, MA.

Read More on AVRO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More